IceCure Medical (ICCM) has received a Notice of Allowance for its invention titled “Cryogenic System Connector” from the USPTO. This is the first global patent issued for the cryogenic system connector, a key component of IceCure’s next-generation liquid nitrogen-based XSense cryoablation system. Several other patent applications for this technology are pending in key markets. XSense and its cryoprobes, which have FDA clearance for all of the indications for which IceCure’s flagship ProSense has already received clearance, has the potential to address additional indications and significant unmet needs in the global tumor ablation market, estimated at $1.67B in 2023 according to Grand View Research.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical files to sell ordinary shares and warrants, no amount given
- IceCure’s ProSense Excels in Global Cryoablation Studies
- IceCure Medical’s ProSense® Shows Promising Trial Results
- IceCure Medical’s cryoablation system shows 96% recurrence free rate
- IceCure’s ProSense Shows High Success in Tumor Treatment